Teva CEO Sees Strong Austedo Demand Cushioning Medicare Pricing Blow in 2027
Teva stock jumps after beating Q3 earnings and boosting its 2026 outlook, powered by 33% branded drug growth.
Share
Why It Matters
Teva made more money than expected this quarter. The company is banking on one popular drug to help when prices drop in 2027.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.